Status:
COMPLETED
Translational Neuroscience Optimization of GlyT1 Inhibitor
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Cognitive Impairments Associated With Schizophrenia
Eligibility:
All Genders
21-65 years
Phase:
PHASE2
Brief Summary
This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this study is to test...
Eligibility Criteria
Inclusion
- 1\) Males or females 21 to 65 years of age (inclusive).
- 2\) Diagnosis of Schizophrenia or Schizoaffective Disorder
- 3\) Able to provide written informed consent.
- 4\) Only CYP2D6 extensive metabolizers.
Exclusion
- 1\) No ongoing acute medical issues
- 2\) Clinically significant ECG abnormality
- 3\) Blood donation within eight weeks of the start of the study
- 4\) Current treatment with Clozapine
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT01911676
Start Date
August 1 2013
End Date
December 1 2018
Last Update
August 19 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519
2
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516